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Most patients with acute myeloid leukemia (AML) express the myeloid antigen CD33 on the surface 
of leukemic blasts. CD33 is a transmembrane receptor that has been targeted for cytotoxic 
monoclonal-antibody-based therapy called gemtuzumab ozogamicin (GO or Mylotarg). With the goal 
of classifying the variability of CD33 expression with disease characteristics of childhood AML, Drs. 
Jessica Pollard and Soheil Meshinchi and colleagues in the CRD division have recently quantified 
CD33 levels on leukemic blasts obtained from 619 de novo childhood AML patients, and correlated 
these levels with the patients’ biological and molecular disease features and clinical outcomes. The 
results show a strong association of high CD33 expression with adverse biological and molecular 
features of the disease and, with multivariate analysis, high CD33 expression is an independent 
predictor of poor outcome. 
Normally, CD33 is expressed in early multilineage hematopoietic progenitors, but decreases as cells 
differentiate into myeloid or monocytic progenitors. Because AML blasts can derive from multiple 
points along myeloid differentiation, CD33 levels may reflect the differentiation or maturity of the 
leukemic progenitor. In addition, several prognostic cytogenetic and molecular features have been 
identified for AML. These include mutations in the tyrosine kinase-associate growth factor receptor 
FLT3, nucleolar phosphoprotein NPM1 and the transcription factor CEBPA. High CD33 expression 
was associated with high-risk FLT3/ITD mutations and inversely associated with low risk 
disease NPM1 mutations and CBF translocations.  Elevated CD33 expression was also strongly 
correlated with poor disease-free and overall survival among patients. Finally, in several univariate 
and multivariate statistical models, high CD33 expression was a significant prognostic factor to 
predict poor outcomes. 
 On-going studies will examine if CD33 levels influence response to GO treatments. A recent phase 
3 clinical trial with a head-to-head comparison of GO to conventional chemotherapy prompted the 
FDA to withdraw approval of GO as a standard AML therapy in 2010. However, GO may benefit a 
specific subgroup of AML patients, likely based on CD33 expression or other associated disease 
factors. Moreover, this work supports studies that examine GO’s ability to improve outcomes for 
patients with low CD33 expression, a group that has previously been excluded from adult GO trials. 
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Finally, inclusion of CD33 levels into risk assessments of patients may further assist in assignment 
to risk stratified AML therapy that may include other CD33-targeting therapeutics. 
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Adapted from images provided by 
the authors. 
CD33 expression on pediatric 
AML blasts is highly variable and 
correlates with disease-free 
survival. A) Distribution of CD33 
expression for the 619 patients; 
B) Correlation of disease-free 
survival with CD33 expression 
(grey = lowest 3 quartiles, black = 
highest CD33 expression 
quartile). 
 
 
